Search - tctmd.com

Displaying 101 - 120 of 143

Sort: Relevancy | Date

News Daily News

Nuevos Roles de las Clínicas Especializadas en Anticoagulación en una Era de Opciones Sin Warfarina

Todd Neale

March 01, 2016

News Daily News

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

Todd Neale

March 01, 2016

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

肺栓塞发作后，二级抗凝效果未持续

L.A. McKeown

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

Presentation

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Presenter: Francis Couturaud

July 10, 2015

News Daily News

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Yael L. Maxwell

July 10, 2015

News Daily News

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Yael L. Maxwell

July 10, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

ISAR-TRIPLE 已发布：6 周与 6 个月三联疗法比较并无净收益

April 29, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

April 29, 2015

Presentation

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Presenter: K.A. Fiedler

April 22, 2015

Advertisement

Nuevos Roles de las Clínicas Especializadas en Anticoagulación en una Era de Opciones Sin Warfarina

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

肺栓塞发作后，二级抗凝效果未持续

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

ISAR-TRIPLE 已发布：6 周与 6 个月三联疗法比较并无净收益

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content